Literature DB >> 12673354

Defective Brca2 influences topoisomerase I activity in mammalian cells.

Iwonna Rahden-Staroń1, Maria Szumiło, Emilia Grosicka, Maria Kraakman van der Zwet, Małgorzata Z Zdzienicka.   

Abstract

The Chinese hamster cell mutant V-C8 is defective in the Brca2 gene (Kraakman-van der Zwet et al., 2002, Cell Biol.; 22: 669). Here we report that V-C8 cells were 10-fold more sensitive to camptothecin, an inhibitor of topoisomerase I, than the parental V79 cells. The level of the relaxation activity of topoisomerase I in nuclear extracts was also lower (4-fold) in V-C8 than V79 cells, in spite of the fact that the level of the topoisomerase I protein was the same in these cells. The survival of V-C8 cells in the presence of camptothecin, the sensitivity of V-C8 topoisomerase I to camptothecin, and the level of the relaxation activity in V-C8 nuclear extract were almost completely restored by transfection of V-C8 cells with the murine Brca2 gene or by the transfer of human chromosome 13 providing the BRCA2 gene. These results indicate that the observed changes in the topoisomerase I activity in V-C8 are due to the defective function of the Brca2 gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673354     DOI: 035001139

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  4 in total

Review 1.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

2.  A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Authors:  Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

3.  Drug therapy for hereditary cancers.

Authors:  Evgeny N Imyanitov; Vladimir M Moiseyenko
Journal:  Hered Cancer Clin Pract       Date:  2011-08-06       Impact factor: 2.857

4.  A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination.

Authors:  Sara M Ambjørn; Julien P Duxin; Emil P T Hertz; Isha Nasa; Joana Duro; Thomas Kruse; Blanca Lopez-Mendez; Beata Rymarczyk; Lauren E Cressey; Thomas van Overeem Hansen; Arminja N Kettenbach; Vibe H Oestergaard; Michael Lisby; Jakob Nilsson
Journal:  Nat Commun       Date:  2021-09-30       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.